under control of the Nes promoter did not elicit the same phenotype. It is important to note, however, that Lepr was among the top 1% most highly expressed genes in sorted nestin-positive mouse cells by microarray analysis 6 , suggesting a potential overlap between the two niche cells, which will require further investigation. Thus, cells associated with the vasculature are the major source of SCF in the bone marrow under steady state. It will be important to evaluate whether the same stromal cells produce the cytokine in situations of regenerative stress, which may shed light on the requirements for building an artificial niche dedicated for HSC expansion.
These two studies bring new exciting angles that add further complexity to bone marrow niches; at the same time, they give us a reminder about the considerable hurdles ahead of us in achieving expansion of HSCs expanded HSCs for clinical use. HSCs require an array of secreted and contact factors-most of which still remain unknown-for their maintenance and proliferation. If these factors are indeed provided by distinct stromal cell types, the challenge of concocting the right ratios of niche constituents to support HSCs for clinical use becomes very substantial. By the same token, one can imagine the translational difficulty in obtaining a renewable source of a good-manufacturing-practice-grade cellular cocktail that would meet the safety thresholds for clinical cell therapy. Further studies will aim at characterizing stromal cell types and, most importantly, the molecular constituents and signals that allow HSC proliferation while maintaining self-renewal.
A major obstacle for future translational HSCbased therapeutics highlighted by the study of Yamazaki et al. 7 concerns the propensity of adult HSCs to remain quiescent. This natural preference was repeatedly shown in several studies where genetic mutations leading to HSC proliferation invariably produce HSC exhaustion 9 . How can we unlock HSCs from their quiescent behavior for the purpose of expansion without reaching exhaustion? It is likely that the coupling of self-renewal and quiescence is not absolute, given that it is not the case for all stem cells; for example, embryonic stem cells can both proliferate and self-renew indefinitely. The ultimate solution, through a greater understanding of the molecular basis of the niche, may lie in some sort of direct or indirect reprogramming of adult (quiescent) HSCs into fetal-like (proliferative) stem cells, a feat that will have to be achieved without increasing the risk of malignancies. Every scientific hurdle, almost by definition, can be overcome. We may be just one breakthrough away from surmounting this one. Historically, secondary AML was thought to be essentially untreatable. However, it is now clear that it comprises a heterogeneous group of disorders, and prognosis and choice of treatment depends upon the cytogenetic and molecular changes found in the particular case under consideration 4 . The study of those at risk for secondary AML provides a unique opportunity for capturing the molecular events driving clonal dominance that eventuates in leukemia.
By combining clinical data with gene sequencing of patient samples, researchers have been able to assess genetic changes in the predisposition setting. For example, a recent study compared whole-genome sequence data from seven individuals with de novo MDS and the secondary AML that emerged. All samples had clonal outgrowths, and 11 recurrently mutated genes in secondary AML were identified, including 9 that were also mutated in the precedent MDS 5 . Assessing a much larger group-bone marrow samples from 439 patients with MDSBejar et al. 6 have also recently identified somatic point mutations in 18 genes, and these genes were associated with ultimate prognostic value 6 . A previous study also described a signature of 38 genes in bone marrow cells that indicated advanced risk of MDS and AML (99.3% positive predictive value) in a selected patient group with a high frequency of therapy-related MDS and AML 1 . Together, these studies are shaping our understanding of not only the specific genes associated with risk of secondary malignancy but also the cellular processes involved. In the two studies where the genes evaluated were not preselected 1, 5 , there was a remarkable heterogeneity and identification of poorly annotated genes and transcriptional regulators. Rather impressive, however, is the implication of metabolism in at least one of the studies 1 . Metabolic derangement is well known in cancer but is less clearly associated with cancer predisposition.
The link between metabolic alteration and cancer was first made by Otto Warburg in the early twentieth century when he provided the provocative observation that cancer cells preferentially consume glucose and metabolize it to lactate even in the presence of oxygen 7 . Aerobic glycolysis was viewed as a corruption of the more highly efficient ATP-generating oxidative phosphorylation associated with normal cells. More modern interpretations, however, argue that the cancer cell is using a modification of metabolic pathways adaptively, shifting in favor of the production of macromolecules needed to meet the biomass demands of rapidly dividing cells 8 . This interpretation of Warburg's observation has accumulated a substantial amount of supporting experimental data. Several studies provide evidence that at least some leukemias use the Warburg effect. PKM2 and HIF1-a, both inducers of the Warburg effect, have both been implicated in AML pathogenesis 9, 10 . Isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations in AML are associated with promotion of aerobic glycolysis through induction of HIF1-a stability 11, 12 and with production of an oncometabolite that inhibits a chromatin modifier, thereby also connecting metabolism with epigenetic control of gene expression 13 .
Left unanswered is whether the metabolic events observed in cancer are always reactive to conditions imposed by transformation or can also be central to it 14 . Does cancer force a change in the way nutritive substrates are used out of the necessity proliferation imposes or is the metabolic shift a primary event, fostering the subsequent development of malignancy? Although the study by Li et al. 1 suggests the latter, as metabolic alterations were in the predictive gene set, other data argue that metabolic changes do little to engender cancer risk. In the case of IDH2, for example, germline mutations (IDH2 R140) in humans that are identical to those found in some human cancers do not provide a predilection to cancer in those individuals 15 . Metabolic alterations may therefore be only minor risk modifiers acting in concert with other changes, such as the epigenetic alterations effected by IDH mutations that could change gene expression such that alteration of the differentiation state would cooperate with a distinct lesion, altering cell growth. Alternatively, the metabolic change may provide the macromolecular substrates needed for new cell generation, enabling a growthprovoking mutation to circumnavigate the full reprogramming of cell metabolism that might otherwise prove limiting.
An entirely unanticipated scenario for the role of metabolism in cancer has recently emerged on the basis of a study of the metabolic interaction between malignant cells and their microenvironment. The relationship of parenchymal cells to their mesenchymal microenvironment in adult tissues is now accepted to be regulatory, in part owing to what has been learned of normal hematopoietic stem and progenitor cells and their niche. The niche concept had a controversial start when proposed in 1978 (ref. 16) . At that time, the concept was in competition with an accepted wisdom that inherent randomness determined whether stem cells would differentiate, divide or self-renew-whether stem cell behavior was cell autonomous. Similarly, the notion that cancer is a cell-autonomous disease has long, perhaps reasonably, been the predominant model driving pathophysiologic evaluations of cancer. But cancer cells clearly exist in the context of tissue and may be viewed as a tissue, not a cell, gone rogue 17 .
A recent study has indicated that cancercell metabolism interacts with metabolic features of the bone marrow microenvironment in a fundamental way 18 . In the setting of chronic lymphocytic leukemia (CLL), bone marrow stroma conversion of cystine to cysteine was crucial for the survival of leukemia cells and their protection against oxidative damage. The authors suggest this may explain why CLL cells do not survive in ex vivo culture 18 . Whereas a dependence on the tumorcell microenvironment has been proposed before, these findings directly implicate the metabolic milieu as part of the dependence. The match between the metabolic activity of therapy-damaged hematopoietic cells and perturbed microenvironmental cells may be needed to achieve the necessary ecosystem for cancer emergence. Going forward, inclusion in new investigations of studies on the microenvironmental cells of those at high risk for secondary leukemia would be of inter- est, particularly in evaluating whether there are changes in genes that create a symbiotic relationship between the malignant cell and its supporting niche. Identification of such parameters may offer therapeutic targets to render the microenvironment less hospitable for the deranged cancer cell. Any progress in helping cancer survivors in their fight against their secondary AML would be worthy of our attention.
